Cell line · CVCL_0317
Papers111
2 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 111
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Targeting GPX4 and FSP1 to exploit ferroptotic vulnerability in Ewing sarcoma. | Front Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A guide to selecting high-performing antibodies for Netrin-1 (UniProt ID: O95631) for use in western blot and immunoprecipitation. | F1000Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An ancient alpharetrovirus lineage in bats: Evolutionary insights and possible roles in reproduction. | PLoS Genet | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Model-dependent GD2 upregulation in Ewing sarcoma with the EZH2 inhibitor tazemetostat: Prerequisites for combination with GD2-specific CAR T cells. | Res Sq | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Systematic Targeting of Protein Complexes with Molecular COUPLrs. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Covalent Inhibition of SHMT2 by Gambogic Acid Induces Ferroptosis Through Mitochondrial Collapse in Triple-Negative Breast Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| p300 Degradation by the p53-SIAH1 Axis Relieves TBK1 Acetylation to Enhance Innate Antiviral Immunity. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MORC3 represses a tandem repeat enhancer to regulate interferon. | EMBO J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MiR-940 Suppresses Ferroptosis by Controlling Expression of Key Regulatory Genes. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Drug Screening of Sarcoma Cells: Finding Shared Sensitivities. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumors. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An Ad5-Based COVID-19 Vaccine Encoding SARS-CoV-2 Spike Glycoprotein Induces Measurable Antibody and Cytokine Responses in Mice. | Biotechnol J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| miR-940 suppresses ferroptosis by controlling expression of key regulatory genes. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Selective Targeting of Immune Checkpoints HLA-G and CD47 Using Novel Dual Signaling Protein DSP216 Promotes Innate Anticancer Immunity. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ERM Inhibition Confers Ferroptosis Resistance through ROS-Induced NRF2 Signaling. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Multi-omic analysis of human PHACTR1 signaling networks. | Commun Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Quantification of Single-Cell Cysteine Using an Electrochemical Nanosensor for Predicting Tumor Disulfidptosis Susceptibility. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeted Delivery of a Potent STING Agonist Payload via an Antibody-Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0317/papers